And then you can excrete parenterally administered drug in the gut, and this is well described that Remicade for instance given intravenously is lost in the stool in severe colitis and Crohn’s disease. So, you know those are reasons why you need more antibody for IBD than you need for the optimal dose of psoriasis. So even if with the peptide antagonists youshow that that you can start to get into the zone of IL-23 parenteral agents for efficacy, I would expect that like antibodies you will need to go further than that to have efficacy and IBD. By contrast with two inhibitors they are really intra cellular acting and you’re eliminating the secretion of the cytokines to begin with, so you wouldn’t expect to have that same target mediated clearance, and I think as you get the IC90 coverage, you should be able to effectively treat Crohn’s disease and ulcerative colitis and that’s what we’re planning to demonstrate in our ongoing Phase 2 trial in Crohn’s disease.
Operator: Thank you. Our last question will come from Alex Thompson with Stifel. Your line is open.
Unidentified Analyst : Hey guys! This is Pat for Alex. Just a quick question on IL-4 receptor alpha program. If you guys could just talk about biological proof of mechanism there and what kind of benchmarks from DP maybe are out there that you guys are taking a look at? Thanks.
Raju Mohan: But first you know, truly excited about an oral agent that’s similar pathway as dupixent . You saw this morning the data from the COPD trials. So its super exciting for us to be in that pathway. We showed early data at the R&D day and we feel comfortable that we’re on our way to really mechanistically exciting approach to how to target the antagonist. I think beyond that you know just wait to stay tuned for it, and we’ll share some more data perhaps into the year. We’re progressing towards our candidates, including showing proof of €“ relevant proof of concept in animal studies and we’re benchmarked against , pretty validated. So initially it’s a mechanistic approach targeting four and 13, and then certainly showing some proof of mechanism data, and then you know similar track to what we’ve done with all our drugs.
In this case differentiation is clear, but I think more importantly targeting defects and like efficacy is going to be the goal for this molecule.
Unidentified Analyst: Thank you.
Operator: Thank you. There are no further questions at this time, so I would like to turn the floor back over to Dr. Raju Mohan for additional or closing remarks.
Raju Mohan : Yes, thank you all. Thank you for participating. Thank you, that were some great questions. Thank you for listening to us. It almost seems like we need another R&D day here, because obviously we’re very passionate about the programs. We understand our molecules; we understand differentiation and we’d love to discuss this dialogue with you. So thank you all again and I look forward to the next discussion.
Operator: Thank you ladies and gentlemen. This concludes today’s Ventyx Biosciences fourth quarter and full year 2022 earnings conference call. Please disconnect your lines at this time and have a wonderful day!
